Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 10/20 | 0.40 |
| ▸ | CTSL | P07711 | 8/20 | 0.37 |
| ▸ | CTSB | P07858 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624289 | 0.86 | CTSK (0.48) | CTSKCTSLCTSBALDH1A1CTSS | |
| SCHEMBL13624318 | 0.86 | CTSL (0.45) | CTSKCTSLCTSBCTSS | |
| SCHEMBL13624434 | 0.84 | CTSK (0.41) | SMN1; SMN2CTSKCTSLCTSBLMNA | |
| SCHEMBL13624310 | 0.84 | CTSK (0.53) | CTSKCTSLCTSBCTSS | |
| SCHEMBL13624391 | 0.84 | CTSK (0.40) | HTTCTSKCTSLCTSBCTSS | |
| SCHEMBL13624316 | 0.83 | CTSK (0.39) | CTSKCTSLCTSBCTSS | |
| SCHEMBL13624312 | 0.83 | CTSK (0.41) | CTSKCTSLCTSBCTSS | |
| SCHEMBL13624315 | 0.82 | CTSK (0.40) | CTSKCTSLCTSBCTSSMAPT | |
| SCHEMBL13624430 | 0.82 | CTSK (0.40) | CTSKCTSLCTSBCTSS | |
| SCHEMBL13624397 | 0.81 | CTSK (0.39) | CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | SMN1; SMN2 4525/4885NPC1 501/4885HTT 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.